Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Treasury Shares (2016 - 2025)

Theravance Biopharma (TBPH) has disclosed Treasury Shares for 10 consecutive years, with $3.7 million as the latest value for Q3 2025.

  • On a quarterly basis, Treasury Shares rose 9733.15% to $3.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was $3.7 million, a 9733.15% increase, with the full-year FY2024 number at $4.0 million, changed N/A from a year prior.
  • Treasury Shares was $3.7 million for Q3 2025 at Theravance Biopharma, down from $4.1 million in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $15.6 million in Q3 2023 to a low of $38000.0 in Q3 2024.
  • A 4-year average of $6.6 million and a median of $4.5 million in 2024 define the central range for Treasury Shares.
  • Peak YoY movement for Treasury Shares: plummeted 99.76% in 2024, then skyrocketed 9733.15% in 2025.
  • Theravance Biopharma's Treasury Shares stood at $12.7 million in 2022, then rose by 22.61% to $15.6 million in 2023, then tumbled by 74.68% to $4.0 million in 2024, then decreased by 5.53% to $3.7 million in 2025.
  • Per Business Quant, the three most recent readings for TBPH's Treasury Shares are $3.7 million (Q3 2025), $4.1 million (Q2 2025), and $4.5 million (Q1 2025).